Comparison between treated vessels in the MTX group and non-MTX group. Values are n (%) unless otherwise specified.
| Variables | MTX, n = 29 | Non-MTX, n = 12 | p |
|---|---|---|---|
| General characteristics | |||
| Female | 14 (48.3) | 5 (41.7) | 0.744 |
| HTN | 17 (58.6) | 5 (41.7) | 0.493 |
| Smoking | |||
| Never smoked | 17 (58.6) | 6 (50.0) | 0.620 |
| Ex-smoker | 8 (27.6) | 5 (41.7) | |
| Current smoker | 4 (13.8) | 1 (8.3) | |
| Statin | 25 (86.2) | 12 (100.0) | 0.302 |
| RA characteristics | |||
| RA duration, yrs, median (IQR) | 6.7 (2.2–12.3) | 4.0 (3.2–17.2) | 0.896 |
| Seropositive | 20 (69.0) | 8 (66.7) | > 0.999 |
| MTX dose, mg/week | 12.5 (10.0–15.0) | N/A | N/A |
| csDMARD other than MTX | 26 (89.7) | 12 (100.0) | |
| Hydroxychloroquine | 22 (84.6) | 4 (33.3) | 0.543 |
| Sulfasalazine | 5 (19.2) | 11 (91.7) | |
| Leflunomide | 3 (11.5) | 1 (8.3) | |
| Tacrolimus | 2 (7.7) | 2 (16.7) | |
| NSAID | |||
| None | 9 (31.0) | 9 (75.0) | 0.102 |
| Naproxen | 5 (17.2) | 1 (8.3) | |
| Celecoxib | 6 (20.7) | 2 (16.7) | |
| Aceclofenac | 2 (6.9) | 0 (0.0) | |
| Meloxicam | 7 (24.1) | 0 (0.0) | |
| Cumulative dose of corticosteroid*, median (IQR) | 1.08 (0.00–4.39) | 0.36 (0.00–2.00) | 0.601 |
| DAS28-CRP, median (IQR) | 1.54 (1.36–1.90) | 1.51 (1.25–1.93) | 0.524 |
| Risk factors of ISR | |||
| Age, yrs, median (IQR) | 68.0 (59.5–71.0) | 65.5 (59.0–73.0) | 0.703 |
| DM | 13 (44.8) | 5 (41.7) | > 0.999 |
| Vessel disease | |||
| 1-vessel disease | 13 (44.8) | 2 (16.7) | 0.190 |
| 2-vessel disease | 11 (37.9) | 8 (66.7) | |
| 3-vessel disease | 5 (17.2) | 2 (16.7) | |
| Ostial lesion | 3 (10.3) | 2 (16.7) | 0.620 |
| LAD involvement | 17 (58.6) | 4 (33.3) | 0.181 |
| Treatment of multiple lesions | 8 (27.6) | 7 (58.3) | 0.083 |
| Type of DES | |||
| 1st generation | 11 (37.9) | 5 (41.7) | > 0.999 |
| 2nd generation | 18 (62.1) | 7 (58.3) | |
| Diameter, mm, median (IQR) | 3.00 (3.00–3.50) | 3.00 (2.81–3.00) | 0.142 |
| Length, mm, median (IQR) | 29.0 (22.5–47.5) | 21.0 (15.0–30.3) | 0.025 |
| ISR | 0 (0.0) | 4 (33.3) | 0.005 |
↵* g of prednisolone or its equivalent. MTX: methotrexate; HTN: hypertension; RA: rheumatoid arthritis; IQR: interquartile range; NSAID: nonsteroidal anti-inflammatory drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28-CRP: 28-joint count Disease Activity Score using C-reactive protein; ISR: in-stent restenosis; DM: diabetes mellitus; LAD: left anterior descending artery; DES: drug-eluting stent; N/A: not applicable.